SLC5A2 and heart failure: The risks of dialysis (odds ratio [OR]: 0.50 and 95% CI: 0.31–0.79), major adverse cardiovascular events (OR: 0.29 and 95% CI: 0.22–0.38), heart failure (OR: 0.66 and 95% CI: 0.52–0.83), urinary tract infection (OR: 0.45 and 95% CI: 0.22–0.92), graft rejection (OR: 0.73, 95% and CI: 0.64–0.83), and all‐cause mortality (OR: 0.40 and 95% CI: 0.27–0.59) were significantly lower in the SGLT2 inhibitor group.